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INTRODUCTION
Metastatic carcinomas are the largest group of malignant
tumors of the liver. The majority arise from bronchogenic,
colorectal, prostate, breast, and pancreatic cancers. Ovarian
serous carcinoma is the most common form of epithelial ova-
rian cancer, and accounts for 40% to 50% of all such tumors,
which spread to vital organ parenchyma, such as the lung
and liver, and occur in 2-3% of the patients. Furthermore,
parenchymal liver metastasis from cystic ovarian adenocar-
cinoma is very rare (1-3). The number of studies that have
evaluated the benefit of hepatic resection of metachronous
metastases from gynecologic cancer is very small, but recently
some authors have reported that hepatic resection of meta-
chronous metastases from gynecologic carcinoma can be per-
formed safely, and may help prolong survival in carefully
selected patients (4). We report a case in which the resection
of metastatic liver neoplasm from ovarian serous cystadeno-
carcinoma was done 7 yr after initial treatment.
CASE REPORT
A 48-yr-old oriental housewife was admitted to the Depart-
ment of Surgery in Severance Hospital, Yonsei University
College of Medicine with mild abdominal discomfort in the
right lower quadrant. She had previously received total abdo-
minal hysterectomy with bilateral salpingo-oophorectomy
due to serous papillary carcinoma of both ovaries at another
hospital in August 1993 and had received 6 cycles of chemo-
therapy with cisplatin and alkyloxan, after the surgical treat-
ment. She had a history of a pulmonary tuberculosis 20 yr
before, which was treated with medication. Her father died
from laryngeal cancer and her elder sister had ovarian cancer.
She visited a private clinic with mild abdominal discomfort
and hepatic mass was detected by ultrasonographic exami-
nation. She was transferred to our hospital for further evalu-
ation and treatment. 
The patient complained of easy fatigability and right lower
quadrant discomfort. Vital signs on admission showed blood
pressure of 110/70 mmHg, body temperature 36.8℃, res-
piration rate 18/min, heart rate 80/min. The findings from
physical examination was unremarkable, except slightly pale
conjunctivae and operative scars on the lower midline area.
She looked anemic, with a hemoglobin 9.8 g/dL, and hema-
tocrit of 30.4%. Serum albumin, bilirubin, and aspartate
aminotransferase (AST)/alanine aminotransferase (ALT) were
all within the normal ranges. Alkaline phosphatase level was
slightly increased at 146 IU/L. A tumor marker study showed
alpha-fetoprotein (AFP) 0.97 IU/mL, carcinoembryonic anti-
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Hepatic Resection of Metastatic Tumor from Serous 
Cystadenocarcinoma of the Ovary
Metastatic carcinomas are the largest group of malignant tumors of the liver. But
parenchymal liver metastasis from cystic ovarian adenocarcinoma is very rare.
We report a case in which the resection of metastatic liver neoplasm from ovari-
an serous cystadenocarcinoma was done 7 yr after initial treatment. A 48-yr-old
oriental housewife complained of easy fatigability and right lower quadrant dis-
comfort. The hepatic mass was detected by ultrasonographic examination. Serum
albumin, bilirubin, and aspartate aminotransferase/alanine aminotransferase were
normal. Alkaline phosphatase level was slightly increased at 146 IU/L. A tumor
marker study showed alpha-fetoprotein 0.97 IU/mL, carcinoembryonic antigen
0.965 ng/mL, cancer antigen 125 1,267 ng/mL and CA 19-9 106.1 ng/mL. The
operation involved cholecystectomy and segmentectomy VI and VII of the liver.
The patient recovered from the surgery without any complication. On the 10th
postoperative day, the patient received a single-regimen chemotherapy with pacli-
taxel (Taxol, 155 mg/m2BSA) and was discharged. She has been carefully fol-
lowed-up without any evidence of recurrence after completion of the remaining 5
cycles of chemo-therapy, at intervals of three weeks. 
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gen (CEA) 0.965 ng/mL, cancer antigen (CA) 125 1267 ng/
mL, and CA19-9 106.1 ng/mL. Chest posteroanterior radio-
graphy examination showed an inactive old tuberculous lesion
in the right upper lung field but no metastatic lesions. Ab-
dominal compted tomography revealed a 8.8×7.6 cm-sized
lobulated mass lesion in segment VI, VII with central necro-
sis and minimal heterogeneous peripheral en-hancement
(Fig. 1). There was no abnormal fluid collection or patho-
logical lymphadenopathy in the peritoneal cavity, and no
evidence of metastases on bone scan. ICG R15 examination
was 2.5%, and we decided to perform liver resection, under
the impression of a metastatic neoplasm of liver. The opera-
tion involved cholecystectomy and segmentectomy VI and
VII of the liver. During the operation, three resection mar-
gins were sent for frozen pathology, and were reported to be
negative for tumor extension. The resected liver showed a
solid, grayish tan, and firm mass with multifocal necrosis
(Fig. 2). The margin of the tumor was irregular and showed
infiltrative growth. The mass showed solid sheets of small,
uniform, dark cells that often were slightly spindled. The
tumor cells showed marked cytological atypia (Fig. 3). The
cellular papillae and psammoma bodies were rarely found.
The mucin production or sinusoidal pattern of tumor cells
was not found microscopically. The pathological features of
the ovarian tumors, which had been resected 7 yr before, were
reviewed and they were similar to those of the hepatic tumor,
although the papillary growth was vague and cellular differ-
entiation was poor in the hepatic lesion than in the previous
ovarian tumor. The liver mass was diagnosed as metastatic
serous carcinoma from the ovary. The patient recovered from
the surgery without any complication. On the 10th postop-
erative day, the patient received a single regimen chemo-
therapy with paclitaxel (Taxol, 155 mg/m2 BSA) and was dis-
charged. She has been carefully followed up without any evi-
dence of recurrence after completion of the remaining 5 cycles
of chemotherapy, at three weeks' intervals. 
Fig. 1. Enhanced CT showing 8.8×7.6 cm sized lobulated mass
lesion on segment VI and VII of the liver. The mass shows central
necrotic area and minimal, heterogenous peripheral enhancement.
Fig. 3. Microscopic feature of metastatic serous carcinoma. The
larger nodule shows characteristic celluar papillae (H&E,×100).
Fig. 2. Gross feature of metastatic serous carcinoma. The resect-
ed liver shows a solid, grayish tan, and firm mass with multifocal
necrosis.
cmYUMC S00-7038
Hepatic Resection of Metastatic Serous Cystadenocarcinoma of Ovary 417
DISCUSSION
The liver is the commonest site of blood-borne metastases
from the abdominal viscera, and the most frequent site for
metastatic growths, other than the lymph nodes (5). Metastat-
ic carcinoma occurs much more frequently in the liver than
primary hepatocelluar carcinoma. Patients with metastatic
involvement of the liver present with major symptoms, in-
cluding hepatic pain, hepatomegaly, ascites, and jaundice.
Anorexia and weight loss are almost constant findings. He-
patomegaly and hepatic tenderness are frequently noted and
palpation may reveal a distinct nodularity of the liver in about
half the cases. The alkaline phosphatase level is increased in
over 80 percents of patients and the AST level is increased
in approximately two-thirds of the patients. Serum AFP de-
termination is a good tumor marker for primary hepatocel-
luar carcinoma but in metastatic carcinoma it is negative (6).
Serial follow-up for the tumor markers of specific tumors,
such as CEA, CA 19-9, and CA 125, is helpful for diagnosis.
In our patient, the CA 125 level was highly elevated at 1,267
ng/mL and the CA 19-9 was also elevated at 106.1 U/mL.
Although CA 125 can be observed in a variety of benign con-
ditions and other nongynecologic malignancies, it is elevated
in 80% of epithelial ovarian cancers. These tumor markers
may be useful in helping to predict the potential for malig-
nancy preoperatively. If elevated, they can be used to moni-
tor the response to therapy and detect early recurrence (3). 
Imaging studies also play an important role in determining
liver metastases. The hepatic metastatic tumor from cystic
ovarian carcinoma may manifest as a well-defined cystic lesion
or as a solid mass, and this solid mass shows delayed enhance-
ment on contrast-enhanced CT imaging. Furthermore, rapid
cystic formation and subcapsular extension is frequently seen
(7). CT findings of our patient were compatible with the
above descriptions. The level of specific tumor marker of
primary cancer was useful and imaging studies were very
helpful for the diagnosis of metastatic lesions in the liver
from ovarian serous cystadenocarcinoma. 
Hepatic resection for a secondary malignant growth can
be performed safely with a real possibility of cure in selected
instances (8). Surgical treatment of hepatic metastases should
be considered only if (a) the control of the primary tumor is
accomplished or anticipated, (b) there are no systemic or intra-
abdominal metastases, (c) the patient's condition is compat-
ible with the major operative procedure, and (d) the extent
of hepatic involvement is such that resection and total extir-
pation of the metastases is feasible (6). Resection of hepatic
metastases from carcinomas of the colon and rectum appear
to extend the survival time in appropriately selected patients,
and selection criteria have been widely published. Similar
data for patients with hepatic metastases from primary sites
other than the colon and rectum are lacking (9). However,
recently some authors have reported that hepatic resection
of metachronous metastases from gynecologic carcinomas
including ovarian serous cystadenocarcinoma could be per-
formed safely and might help prolong survival in carefully
selected patients (4, 10). 
Ovarian epithelial cancers spread primarily by exfoliation
of cells into the peritoneal cavity, by lymphatic dissemina-
tion, and by hematogenous spread. The most common and
earliest mode of dissemination of ovarian cancer is through
the exfoliation of cells that implant along the surfaces of the
peritoneal cavity. Therefore, metastases are typically seen on
the posterior cul-de-sac, paracolic gutter, right hemidiaph-
ragm, liver capsule, and the peritoneal surfaces of the intest-
ines and their mesenteries, and the omentum. Hematoge-
nous dissemination at the time of diagnosis is uncommon
and liver metastases from epithelial ovarian cancers are less
frequent than other ovarian cancers, for example, stromal
tumors, sarcomas, and germ cell tumors (11). Total of 224
cases of variable hepatic resection were performed for meta-
static tumor from March 1986 to May 2000 in our hospi-
tal. Among them 77 cases were metastatic liver neoplasms
from non-colorectal primary tumors (34.8%). There were
only 2 cases of hepatic resection for metastases from ovarian
cancer (0.9% of the total number of hepatic resections for
metastatic tumors). Various chemotherapeutic agents have
been found to be active against ovarian serous cystadenocar-
cinoma. This additional therapy is indicated for patients in
which the disease is more poorly differentiated or in whom
there are malignant cells either in the ascitic fluid or in peri-
toneal washings (1). Single-agent cisplatin or cisplatin-based
combination therapy is the most effective regimen. Recent-
ly, paclitaxel (Taxol), a microtubule stabilizer, was found to
have significant activity in many cancers, and reported to be
the drug of choice in the treatment of patients with cancer
of the ovary and Fallopian tube that are resistant to conven-
tional chemotherapy (12). Oliverio et al. reported the efficacy
of paclitaxel in the second-line treatment of refractory and
relapsed ovarian cancer patients. They concluded that this
therapy is an acceptable treatment with a good safety profile,
and can be safely administered at a dosage of 175 mg/m2
(13). For patients treated initially with platinum therapy,
paclitaxel has therapeutic responses occurring in 20-36% of
patients (1). Our patient had already received 6 cycles of
chemotherapy with cisplatin and alkyloxan after the first
operation for ovarian cancer. Although all resection margins
were negative for malignancy, the pathologic diagnosis of
the tumor was poorly-differentiated adenocarcinoma with
areas of necrosis and lymphovascular invasion and the tumor
extended to the soft tissue of the Glisson's capsule. So we
performed adjuvant chemotherapy with paclitaxel after hep-
atic resection.
In summary we report a rare case in which hepatic resec-
tion was done for metastatic liver neoplasm from serous cys-
tadenocarcinoma of the ovary. The patient should be care-
fully followed-up with physical examinations, serial blood
cell counts, blood chemistry, imaging studies, and the eval-
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uation of tumor marker levels.
REFERENCES
1. Berek JS, Adashi EY, Hillard PA. Ovarian cancer. In Novak ER, eds.
Novak's Gynecology. 12th ed. Baltimore: Williams & Wilkins, 1996;
1155-92.
2. Leifer DM, Chan TW. Liver metastases from ovarian cystadenocar-
cinoma masquerading on CT as lobar fatty infiltration. J Comput
Assist Tomogr 1993; 17: 816-8.
3. Scott JR, Saia PJ, Hammond CB, Spellacy WN. Disease of the ovary
and fallopian tube. In Danforth DN, Saia PJ, eds. Danforth's Obstet-
rics and Gynecology 8th ed. Baltimore; Lippincott, Williams & Wil-
kins, 1999; 892-901.
4. Chi DS, Fong Y, Venkatraman ES, Barakat RR. Hepatic resection
for metastatic gynecologic carcinomas. Gynecol Oncol 1997; 66:
45-51. 
5. Lygidakis NJ, Pearl A. Metastatic liver disease-a review. Hepato-
gastroenterology 1997; 44: 1484-7.
6. Schwartz SI, Shires GT, Spencer FC. Metastatic neoplasms in liver.
In Schwatz SI eds. Principles of Surgery 6th ed. NewYork: McGraw-
Hill, 1994: 1339-40.
7. Tang Y, Yamashita Y, Ogata I, Namimoto T, Abe Y, Urata J, Taka-
hashi M. Metastatic liver tumor from cystic ovarian carcinomas: CT
and MRI appearance. Radiat Med 1999; 17: 265-70.
8. Cobourn CS, Makowka L, Langer B, Taylor BR, Falk RE. Exami-
nation of patient selection and outcome for hepatic resection for meta-
static disease. Surg Gynecol Obstet 1987; 165: 239-46.
9. Wolf RF, Goodnight JE, Krag DE, Schneider PD. Result of resection
and proposed guidelines for patient selection in instances of noncol-
orectal hepatic metastases. Surg Gynecol Obstet 1991; 173: 454-60.
10. Harrison LE, Brennan MF, Newman E, Fortner JG, Picardo A, Blum-
gart LH, Fong Y. Hepatic resection for noncolorectal, nonneuroen-
docrine metastases: a fifteen-year experience with ninety-six patients.
Surgery 1997; 121: 625-32.
11. Rose PG, Piver MS, Tsukada Y, Lau TS. Metastatic patterns in his-
tologic variants of ovarian cancer. An autopsy study Cancer 1989;
64: 1508-13.
12. Cai S, Tang J, Fan J. A clinical report of refractory carcinoma of ovary
and fallopian tube treated with taxol. Zhonghua Zhong Liu Za Zhi
(Chinese J Oncol) 1995; 17: 135-8.
13. Oliverio G, Canuti D, Tononi A, Scarpellini M, Danzini I, Galli I,
Ravaioli A. Paclitaxel efficacy and tolerability in second-line treat-
ment of refractory and relapsed ovarian cancer patients. J Chemo-
therapy 1999; 11: 301-5.
